Abivax SA American Depositary Shares ABVX

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

• Zacks Investment Research 18 sept

  4 Biotech Stocks to Watch as Potential Takeover Targets

  Biotech M&A activity has accelerated sharply in 2026, with deal value reaching $130 billion in H1 alone. Four biotech companies—Abivax, Iovance Biotherapeutics, Viking Therapeutics, and BioCryst Pharmaceuticals—are highlighted as potential acquisition targets due to their differentiated late-stage assets and strategic positioning in high-growth therapeutic areas including immunology, oncology, obesity, and rare diseases.

  

• GlobeNewswire Inc. 7 sept

  Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight

  The ulcerative colitis market is experiencing significant growth with emerging therapies addressing unmet needs in moderate-to-severe disease. The market, valued at approximately USD 9.4 billion in 2025, is projected to expand at a CAGR of 7.6% through 2036. Five promising late-stage candidates—Obefazimod (Abivax), Tulisokibart (Merck), Afimkibart (Roche), Icotrokinra (J&J/Protagonist), and Duvakitug (Teva/Sanofi)—are reshaping the treatment landscape with novel mechanisms targeting IL-23 and TL1A pathways, while established biologics and oral therapies continue to maintain market presence.

  

• The Motley Fool 7 jul

  3 Soaring Stocks That May Have More Upside Ahead

  The article highlights three biotech and semiconductor stocks that have more than doubled in the past 12 months but may have further upside potential. Abivax is advancing obefazimod for ulcerative colitis with strong clinical results. Krystal Biotech is generating strong revenue growth from its approved DEB treatment Vyjuvek with significant market expansion opportunities. Marvell Technology is capitalizing on AI infrastructure spending demand for custom chips as an alternative to Nvidia's GPUs.

  

• GlobeNewswire Inc. 1 jul

  Abivax announces trading resumption of its ordinary shares on Euronext Paris

  Abivax SA resumed trading of its ordinary shares on Euronext Paris on July 1, 2026, following a temporary halt. The company announced the pricing of an oversubscribed and upsized public offering of American Depositary Shares, increased from the previously announced $600M to $800M at $125.00 per share.

  

• GlobeNewswire Inc. 1 jul

  Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris

  Abivax SA announced a temporary suspension of its ordinary shares trading on Euronext Paris starting July 1, 2026 at market opening. The suspension is related to the company's public offering of American Depositary Shares (ADS) in the United States to confirm investor allocations and announce final offering terms. Trading is expected to resume around 15:30 CEST the same day.